Regorafenib for gastrointestinal malignancies: From preclinical data to clinical results of a novel multi-target inhibitor

BioDrugs

Volumn 27, Issue 3, 2013, Pages 213-224

  Aprile, Giuseppe ^a   MacErelli, Marianna ^a   Giuliani, Francesco ^b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IMATINIB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PEMETREXED; PLACEBO; REGORAFENIB; SORAFENIB; SUNITINIB; VANDETANIB; VATALANIB;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DESQUAMATION; DIARRHEA; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SKIN REACTION; HEREDITARY HYPERTENSION; HOARSENESS; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; LIVER CELL CARCINOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES;

EID: 84878556100     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0014-9     Document Type: Review

References (65)

1. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol. 2003;21:255-61. (Pubitemid 36314808)
2. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355-65. (Pubitemid 32467045)
3. Hunter T. Signaling: 2000 and beyond. Cell. 2000;100:113-27.
4. Cohen P. Protein kinases: the major drug targets of the twenty-first century? Nat Rev Drug Discov. 2002;1:309-15. (Pubitemid 37361447)
5. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-6. (Pubitemid 32267975)
6. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science. 2002;298:1912-34. (Pubitemid 35425239)
7. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28-39.
8. Sikkema AH, den Dunnen WF, Diks SH, et al. Optimizing targeted cancer therapy: towards clinical application of systems biology approaches. Crit Rev Oncol Hematol. 2012;82:171-86.
9. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80. (Pubitemid 34879334)
10. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34. (Pubitemid 46089673)
11. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007;356:115-24. (Pubitemid 46089672)
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32. (Pubitemid 41058344)
13. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6. (Pubitemid 46972777)
14. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
15. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
16. Gossage L, Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res. 2010;16:1973-8.
17. Sawyers CL. Cancer: mixing cocktails. Nature. 2007;449:993-6. (Pubitemid 350014587)
18. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010;10:130-7.
19. E7050 in combination with sorafenib versus sorafenib alone as first line therapy in patients with hepatocellular carcinoma. ClinicalTrials.gov Identifier: NCT01271504. National Institutes of Health. http://www. clinicaltrials.gov.
20. Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23:329-36. (Pubitemid 41094421)
21. Bayer and Onyx settle over regorafenib [editorial]. Nat Rev Drug Discov 2011;10:804-5.
22. Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin Investig Drugs. 2012;21:879-89.
23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
24. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685-93. (Pubitemid 36749217)
25. Carmeliet P. VEGF has a key mediator of angiogenesis in cancer. Oncology. 2005;69(Suppl. 3):4-10. (Pubitemid 41680947)
26. Sithoy B, Nagy JA, Dvorak HF, et al. Anti VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012;72:1909-14.
27. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumors after failure of imatinib: a randomized controlled trial. Lancet. 2006;368:1329-38. (Pubitemid 44528723)
28. Giuliani F, Colucci G. Is there something other than imatinib mesilate in therapeutic options for GIST? Expert Opin Ther Targets. 2012;16(Suppl. 2):S35-43.
29. Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean Gastrointestinal Stromal Tumors Study Group. Invest New Drugs. 2012;30:2377-83.
30. Ryu M, Park SH, Ryoo B, et al. A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study [abstract 10010]. 2011 ASCO Annual Meeting. J Clin Oncol. 2011;29(Suppl).
31. Prazeres H, Couto JP, Rodrigues F, et al. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. Endocr Relat Cancer. 2011;18:401-12.
32. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134-41.
33. Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res. 2010;16:5936-41.
34. Plaza-Menacho I, Burzynski GM, de Groot JW, et al. Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet. 2006;22:627-36. (Pubitemid 44602269)
35. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245-55.
36. Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs. 2009;18:1893-905.
37. Cassano A, Bagala C, Battelli C, et al. Expression of vascular endothelial growth factor, mitogen-activated protein kinase and p53 in human colorectal cancer. Anticancer Res. 2002;22:2179-84. (Pubitemid 34857040)
38. Dienstmann R, Tabernero J. BRAF as a target cancer therapy. Anticancer Agents Med Chem. 2011;11:285-95.
39. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54. (Pubitemid 34716871)
40. Yokota T, Ura T, Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104:856-62.
41. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-14.
42. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16.
43. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2:227-35.
44. Schmieder R, Ellinghaus P, Scholze A., et al. Regorafenib (BAY 73-4506): anti-metastatic activity in a mouse model of colorectal cancer [abstract no. 2337]. 2012 AACR Annual Meeting, 2012 March 31-April 4, Chicago (IL).
45. Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658-67.
46. Strumberg D, Scheulen ME, Schulteis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722-7.
47. Shimizu T, Tolcher AW, Patnaik A, et al. Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors [abstract no. 3035]. 2010 ASCO Annual Meeting, 2010 June 4-8, Chicago (IL).
48. Kies MS, Blumenschein GR Jr, Christensen O, et al. Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC) [abstract no. 7585]. 2010 ASCO Annual Meeting. J Clin Oncol. 2010;28:(Suppl. 15s).
49. Eisen T, Joensuu H, Nathan P, et al. Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer [abstract no. 5033]. 2009 ASCO Annual Meeting. J Clin Oncol. 2009;27:(Suppl. 15s).
50. Bolondi L, Tak WY, Gasbarrini A, et al. Phase II safety study of the oral multikinase inhibitor regorafenib (BAY 73-4506) as second-line therapy in patients with hepatocellular carcinoma (HCC) [abstract]. Eur J Cancer. 2011;7:6576.
51. George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012;30:2401-7.
52. Van Den Abbeele AD, Tanaka Y, Locascio T, et al. Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx) [abstract no. 10050]. 2011 ASCO Annual Meeting. J Clin Oncol. 2011;29(Suppl. 15s).
53. Grothey A, Van Cutsem E, Sobrero AF, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303-12.
54. Van Cutsem E, Sobrero A, Siena S, et al. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) [abstract no. 3502]. 2012 ASCO Annual Meeting. J Clin Oncol. 30;(Suppl).
55. Regorafenib in subjects with metastatic colorectal cancer (CRC) who have progressed after standard therapy (CONSIGN). ClinicalTrials.gov Identifier: NCT01538680. National Institutes of Health. http://www.clinicaltrials.gov.
56. Demetri GD, Reichardt P, Kang Y, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295-302.
57. Determination of safety, efficacy, and pharmacokinetics of "regorafenib" combined with pemetrexed and cisplatin in patients with nonsquamous non-small cell lung cancer. ClinicalTrials.gov Identifier: NCT01187615. National Institutes of Health. http://www.clinicaltrials.gov.
58. First line treatment of metastatic colorectal cancer with mFOLFOX6 in combination with regorafenib. CORDIAL. ClinicalTrials.gov Identifier: NCT01289821. National Institutes of Health. http://www.clinicaltrials.gov.
59. Regorafenib + FOLFIRI versus placebo + FOLFIRI as 2nd line Tx in K-RAS/BRAF mutant metastatic colorectal cancer. ClinicalTrials.gov Identifier: NCT01298570. National Institutes of Health. http://www.clinicaltrials.gov.
60. Study to determine safety, pharmacokinetics, pharmacodynamics of BAY73-4506 in combination with mFOLFOX6 or FOLFIRI. ClinicalTrials.gov Identifier: NCT00934882. National Institutes of Health. http://www. clinicaltrials.gov.
61. Motzer RJ, Hutson TE, Olsen M, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30:1371-7.
62. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27:3141-7.
63. A Study of avastin (bevacizumab) plus crossover fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. ClinicalTrials.gov identifier: NCT0070010. National Institutes of Health. http://www. clinicaltrials.gov.
64. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499-506.
65. T670I gatekeeper mutation in gastrointestinal stromal tumors. Clin Cancer Res. 2007;13:4874-81. (Pubitemid 47294795)